原发性肝癌是常见的严重威胁人类健康的恶性肿瘤之一,老年人群中发病率逐渐上升,但老年患者存在着治疗不足的风险。随着科学技术的不断进步,临床上原发性肝癌的治疗方法发展迅速,FUAS作为唯一的体外的非侵入性的肿瘤局部治疗方式,现广...原发性肝癌是常见的严重威胁人类健康的恶性肿瘤之一,老年人群中发病率逐渐上升,但老年患者存在着治疗不足的风险。随着科学技术的不断进步,临床上原发性肝癌的治疗方法发展迅速,FUAS作为唯一的体外的非侵入性的肿瘤局部治疗方式,现广泛应用于早期肝癌、中晚期肝癌、困难部位的肝癌等方面。现就FUAS在老年原发性肝癌患者中的治疗机制、临床应用及研究进展方面进行综述。Primary liver cancer is a common and aggressive malignancy that significantly impacts human health, with its incidence steadily increasing among the elderly population. However, elderly patients are often at risk of receiving suboptimal treatment. With ongoing advancements in medical science and technology, the clinical management of primary liver cancer has seen rapid progress. Focused ultrasound ablation surgery (FUAS) stands out as the only extracorporeal, non-invasive, and localized tumor treatment, and has become widely adopted for early-stage hepatocellular carcinoma, as well as for intermediate- and advanced-stage cases, and tumors located in challenging anatomical sites. This article provides an overview of the therapeutic mechanisms, clinical applications, and research advancements of FUAS in elderly patients with primary liver cancer.展开更多
文摘原发性肝癌是常见的严重威胁人类健康的恶性肿瘤之一,老年人群中发病率逐渐上升,但老年患者存在着治疗不足的风险。随着科学技术的不断进步,临床上原发性肝癌的治疗方法发展迅速,FUAS作为唯一的体外的非侵入性的肿瘤局部治疗方式,现广泛应用于早期肝癌、中晚期肝癌、困难部位的肝癌等方面。现就FUAS在老年原发性肝癌患者中的治疗机制、临床应用及研究进展方面进行综述。Primary liver cancer is a common and aggressive malignancy that significantly impacts human health, with its incidence steadily increasing among the elderly population. However, elderly patients are often at risk of receiving suboptimal treatment. With ongoing advancements in medical science and technology, the clinical management of primary liver cancer has seen rapid progress. Focused ultrasound ablation surgery (FUAS) stands out as the only extracorporeal, non-invasive, and localized tumor treatment, and has become widely adopted for early-stage hepatocellular carcinoma, as well as for intermediate- and advanced-stage cases, and tumors located in challenging anatomical sites. This article provides an overview of the therapeutic mechanisms, clinical applications, and research advancements of FUAS in elderly patients with primary liver cancer.
